Table 1: Patients characteristics.

CharacteristicsValue

Sex, no (%)
 Male46 (52)
 Female42 (48)
Median age at diagnosis (range)51 (21–83)
Hasford score at diagnosis, no (%)
 Low risk (LR)57 (65)
 Intermediate risk (IR)31 (35)
Sokal score at diagnosis, no (%)
 Low risk60 (68)
 Intermediate risk20 (23)
 High risk8 ()
EUTOS score at diagnosis, no (%)
 Low risk65 (74)
 High risk23 (26)
Hasford score, median value in LR group [min–max]555 [0–766]
Hasford score, median value in IR group [min–max]998 [415–1450]
MMR lost on imatinib (assessed by Hasford score) no (%)
 Low risk20 (35)
 Intermediate risk22 (71)
Median time to MMR loss (range) [months]47 (12–108)
2G-TKI, no (%)
 Dasatinib 100 mg21 (50)
 Nilotinib 800 mg21 (50)
MMR at 3 months of 2G-TKI, no (%)
 Low risk19/20 (86)
 Intermediate risk9/22 (41)
MMR at 18 months of 2G-TKI, no (%)
 Low risk20/20 (100)
 Intermediate risk16/22 (73)
MR ≥ 4.0 at 3 months of 2G-TKI
 Low risk10/20 (50)
 Intermediate risk4/22 (18)
MR ≥ 4.0 at 18 months of 2G-TKI
 Low risk17/20 (77)
 Intermediate risk8/22 (37)